<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJS</journal-id><journal-title-group><journal-title>Hans Journal of Surgery</journal-title></journal-title-group><issn pub-type="epub">2168-5584</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJS.2017.61002</article-id><article-id pub-id-type="publisher-id">HJS-19483</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJS20170100000_21429470.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血清CA19-9异常增高的胆总管结石7例诊治体会
  Experience of Diagnosis and Treatment of 7 Cases of Common Bile Duct Stones with Abnormal Increase of Serum CA19-9
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>立民</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>宗明</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>卓</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>翀</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>宏伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>子旭</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>明文</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>蒙蒙</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>月</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>首都医科大学北京电力医院普外科，北京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>zhangzongming@mail.tsinghua.edu.cn(张宗)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>01</month><year>2017</year></pub-date><volume>06</volume><issue>01</issue><fpage>8</fpage><lpage>12</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   血清CA19-9是一种常见的肿瘤标志物，其升高多见于各种消化系统恶性肿瘤患者，尤其是胆管癌、胰腺癌，对于鉴别胆道良、恶性疾病具有重要参考价值。胆道良性疾病患者，血清CA19-9异常升高者少见。本文结合7例血清CA19-9异常升高的胆总管结石患者的诊治体会，深入探讨胆总管结石患者血清CA19-9异常升高的病因、诊断和治疗，以期有效提高血清CA19-9异常升高的胆道良性疾病患者的诊治效果、避免胆道恶性肿瘤的误诊和误治。 Serum CA19-9 is one of the most common tumor markers whose elevation is common in patients with various malignant tumors of digestive system, especially bile duct carcinoma, pancreatic cancer, which has important reference value in the differential diagnosis of benign and malignant biliary diseases. Patients with benign biliary tract disease, abnormal elevated serum CA19-9 are rare. Based on our experience of abnormal increase of serum CA19-9 in 7 patients with choledocholithiasis, this paper will further investigate the etiology, diagnosis and treatment of bile duct stones in patients with abnormal serum CA19-9 increased, so as to effectively improve the diagnosis and treatment effect of the biliary tract benign disease patients with abnormal elevated serum CA19-9, and to avoid misdiagnosis and mistreatment of biliary tract malignant tumor.
    
  
 
</p></abstract><kwd-group><kwd>胆总管结石，急性胆管炎，血清CA19-9, Common Bile Duct Stones</kwd><kwd> Acute Cholangitis</kwd><kwd> Serum CA19-9</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>血清CA19-9异常增高的胆总管结石7例诊治体会<sup> </sup></title><p>刘立民，张宗明<sup>*</sup>，刘卓，张翀，于宏伟，刘子旭，朱明文，宋蒙蒙，赵月</p><p>首都医科大学北京电力医院普外科，北京</p><disp-formula id="hanspub.19483-formula32"><graphic xlink:href="http://html.hanspub.org/file/2-2280115x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2016年12月21日；录用日期：2017年1月7日；发布日期：2017年1月10日</p><disp-formula id="hanspub.19483-formula33"><graphic xlink:href="http://html.hanspub.org/file/2-2280115x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>血清CA19-9是一种常见的肿瘤标志物，其升高多见于各种消化系统恶性肿瘤患者，尤其是胆管癌、胰腺癌，对于鉴别胆道良、恶性疾病具有重要参考价值。胆道良性疾病患者，血清CA19-9异常升高者少见。本文结合7例血清CA19-9异常升高的胆总管结石患者的诊治体会，深入探讨胆总管结石患者血清CA19-9异常升高的病因、诊断和治疗，以期有效提高血清CA19-9异常升高的胆道良性疾病患者的诊治效果、避免胆道恶性肿瘤的误诊和误治。</p><p>关键词 :胆总管结石，急性胆管炎，血清CA19-9</p><disp-formula id="hanspub.19483-formula34"><graphic xlink:href="http://html.hanspub.org/file/2-2280115x9_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>血清糖类抗原19-9(CA19-9)是一种常见的肿瘤标志物，其升高多见于各种消化系统恶性肿瘤患者，尤其是胆管癌、胰腺癌 [<xref ref-type="bibr" rid="hanspub.19483-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.19483-ref2">2</xref>] 。血清CA19-9升高，对于鉴别胆道良、恶性疾病具有重要参考价值。在胆道良性疾病患者中，尽管血清CA19-9异常升高者少见，但近年来时有报道 [<xref ref-type="bibr" rid="hanspub.19483-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.19483-ref4">4</xref>] 。我院近3年收治7例血清CA19-9异常升高的胆总管结石患者，现结合其诊治体会，深入探讨胆总管结石患者血清CA19-9异常升高的病因、诊断和治疗。</p></sec><sec id="s4"><title>2. 病例资料与方法</title><p>1) 一般资料：我院普外科2013年6月至2016年5月收治胆总管结石患者102例，其中发现CA19-9异常升高者7例(男4例，女3例)，年龄36~89岁，平均年龄(66.7 &#177; 18.4)岁。</p><p>纳入标准：经CT、MRCP或ERCP证实为胆总管结石患者。</p><p>排除标准：既往存在恶性肿瘤病史或本次住院诊断为恶性肿瘤患者。</p><p>2) 术前影像学检查：患者入院后均经B超、CT、MRCP检查，明确胆总管结石诊断，其中单发胆总管结石5例，多发胆总管结石2例(结石数量1.43 &#177; 0.79个，结石大小0.8~ 1.5 cm ，平均直径1.19 &#177; 0.23 cm )，合并急性胆管炎4例、胆囊结石6例、急性胆囊炎5例。</p><p>3) 术前实验室检查：患者术前1天抽血行血常规、高敏C反应蛋白、肝功能、肿瘤标记物检查，结果发现血清CA19-9异常增高，1000~8800 U/L，平均值4248 U/L。</p><p>4) 手术方法：全部患者均接受常规术前检查及准备后手术，经右肋缘下斜切口入腹，分离出胆囊动脉结扎后切断，分离出胆囊管结扎，如胆囊管内镜达0.5 cm以上，行经胆囊管胆总管探查、胆道镜检查、网篮取石术；否则显露胆总管前壁，纵行切开1 cm左右，行胆道镜检查、网篮取石后放置T管，Winslons孔放置引流管后关腹。该7例患者中5例行开腹胆囊切除、经胆囊管胆总管探查、胆道镜检查、网篮取石术，2例行开腹胆囊切除、胆总管切开胆总管探查、胆道镜检查、网篮取石、T管引流术。</p><p>5) 术后治疗和实验室检查：患者术后给予常规输液、抗感染、对症治疗，术后第1天、第7天抽血复查血常规、高敏C反应蛋白、肝功能、肿瘤标记物，结果发现手术前后的血清结合胆红素、γ-谷氨酰转肽酶、CA19-9有显著差异(P &lt; 0.05)，其余实验室检查结果无差异(P &gt; 0.05)，见表1~3。</p><p>6) 治疗效果：全部7例患者术后未发生胰腺炎、胆漏、切口感染等并发症，均康复出院，住院时间9~25天。</p><p>7) 随访：全部患者术后随访6个月，无胆总管结石、胆管炎复发，血清CA19-9正常。</p><p>8) 统计学方法：应用SPSS18.0软件进行统计学分析。先对各项实验室对比指标进行方差分析，如果方差齐，进行方差分析，包括TB、DB、ALP、N(%)、hs-CRP、CEA、AFP；如果方差不齐，用非参数检验的Kruskal Wallis检验得出H值和p值，包括ALT、GGT、WBC、CA19-9。P &lt; 0.05表示差异有统计学意义。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The comparison of preoperative and postoperative hepatic function in 7 cases (</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >时间/指标</th><th align="center" valign="middle" >ALT</th><th align="center" valign="middle" >TB</th><th align="center" valign="middle" >DB</th><th align="center" valign="middle" >GGT</th><th align="center" valign="middle" >ALP</th></tr></thead><tr><td align="center" valign="middle" >术前1 d</td><td align="center" valign="middle" >122.6 &#177; 126.4</td><td align="center" valign="middle" >204.9 &#177; 84.5</td><td align="center" valign="middle" >117.4 &#177; 37.3</td><td align="center" valign="middle" >616.0 &#177; 450.5</td><td align="center" valign="middle" >305.7 &#177; 112.6</td></tr><tr><td align="center" valign="middle" >术后1 d</td><td align="center" valign="middle" >66.7 &#177; 29.3</td><td align="center" valign="middle" >123.9 &#177; 120.8</td><td align="center" valign="middle" >62.6 &#177; 57.8</td><td align="center" valign="middle" >303.1 &#177; 247.6</td><td align="center" valign="middle" >234.0 &#177; 171.5</td></tr><tr><td align="center" valign="middle" >术后7 d</td><td align="center" valign="middle" >31.3 &#177; 22.1</td><td align="center" valign="middle" >83.6 &#177; 99.8</td><td align="center" valign="middle" >40.5 &#177; 55.0</td><td align="center" valign="middle" >109.0 &#177; 65.5</td><td align="center" valign="middle" >130.1 &#177; 95.2</td></tr><tr><td align="center" valign="middle" >统计值</td><td align="center" valign="middle" >H = 5.705</td><td align="center" valign="middle" >F = 2.404</td><td align="center" valign="middle" >F = 3.956</td><td align="center" valign="middle" >H = 8.211</td><td align="center" valign="middle" >F = 3.198</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.058</td><td align="center" valign="middle" >0.119</td><td align="center" valign="middle" >0.038</td><td align="center" valign="middle" >0.016</td><td align="center" valign="middle" >0.065</td></tr></tbody></table></table-wrap><p>表1. 7例患者手术前后肝功能改变比较(<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/2-2280115x11_hanspub.png" xlink:type="simple"/></inline-formula>)</p><p>注：ALT，丙氨酸氨基转移酶，U/L。TB，总胆红素，μmol/L。DB, 结合胆红素，μmol/L。GGT，γ-谷氨酰转肽酶，U/L。ALP，碱性磷酸脂酶，U/L。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The comparison of preoperative and postoperative blood routine and hs-CRP in 7 cases (</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >时间/指标</th><th align="center" valign="middle" >WBC</th><th align="center" valign="middle" >N(%)</th><th align="center" valign="middle" >hs-CRP</th></tr></thead><tr><td align="center" valign="middle" >术前1 d</td><td align="center" valign="middle" >13.3 &#177; 7.1</td><td align="center" valign="middle" >78.9 &#177; 14.4</td><td align="center" valign="middle" >113.7 &#177; 123.1</td></tr><tr><td align="center" valign="middle" >术后1 d</td><td align="center" valign="middle" >13.7 &#177; 3.7</td><td align="center" valign="middle" >84.2 &#177; 5.1</td><td align="center" valign="middle" >81.1 &#177; 75.2</td></tr><tr><td align="center" valign="middle" >术后7 d</td><td align="center" valign="middle" >9.7 &#177; 3.1</td><td align="center" valign="middle" >75.9 &#177; 10.1</td><td align="center" valign="middle" >35.0 &#177; 31.7</td></tr><tr><td align="center" valign="middle" >统计值</td><td align="center" valign="middle" >H = 2.866</td><td align="center" valign="middle" >F = 1.107</td><td align="center" valign="middle" >F = 1.505</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.239</td><td align="center" valign="middle" >0.352</td><td align="center" valign="middle" >0.249</td></tr></tbody></table></table-wrap><p>表2. 7例患者手术前后血常规和高敏C反应蛋白改变比较(<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/2-2280115x13_hanspub.png" xlink:type="simple"/></inline-formula>)</p><p>注：WBC，白细胞，&#215;10<sup>9</sup>/L。N，中性粒细胞比例。hs-CRP，高敏C反应蛋白，mg/L。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The comparison of preoperative and postoperative serum tumor markers in 7 cases (</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >时间/指标</th><th align="center" valign="middle" >CA19-9</th><th align="center" valign="middle" >CEA</th><th align="center" valign="middle" >AFP</th></tr></thead><tr><td align="center" valign="middle" >术前1 d</td><td align="center" valign="middle" >4248.2 &#177; 3462.1</td><td align="center" valign="middle" >2.7 &#177; 1.3</td><td align="center" valign="middle" >2.5 &#177; 1.4</td></tr><tr><td align="center" valign="middle" >术后1 d</td><td align="center" valign="middle" >1346.9 &#177; 2639.9</td><td align="center" valign="middle" >2.4 &#177; 1.3</td><td align="center" valign="middle" >2.7 &#177; 1.5</td></tr><tr><td align="center" valign="middle" >术后7 d</td><td align="center" valign="middle" >46.9 &#177; 30.5</td><td align="center" valign="middle" >2.4 &#177; 1.3</td><td align="center" valign="middle" >2.8 &#177; 1.8</td></tr><tr><td align="center" valign="middle" >统计值</td><td align="center" valign="middle" >H = 15.802</td><td align="center" valign="middle" >F = 0.087</td><td align="center" valign="middle" >F = 0.054</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.917</td><td align="center" valign="middle" >0.948</td></tr></tbody></table></table-wrap><p>表3. 7例患者手术前后血清肿瘤标记物改变比较(<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/2-2280115x15_hanspub.png" xlink:type="simple"/></inline-formula>)</p><p>注：CA19-9，糖蛋白抗原19-9，U/ml。CEA，癌胚抗原，U/ml。AFP，甲胎蛋白，ng/ml。</p></sec><sec id="s5"><title>3. 结果</title><p>将7例患者手术前1天、术后1天、术后7天肝功能指标ALT、GGT进行非参数检验的Kruskal Wallis检验，发现ALT于术前术后相比无显著差异(P &gt; 0.05)；GGT差异较显著(P &lt; 0.05)。将TB、DB、ALP进行方差分析，发现TB及ALP于术前术后相比无显著差异(P &gt; 0.05)；DB差异较显著(P &lt; 0.05)。见表1。</p><p>将7例患者手术前1天、术后1天、术后7天WBC进行非参数检验的Kruskal Wallis检验，发现WBC于术前术后相比无显著差异(P &gt; 0.05)；将N%、hs-CRP进行方差分析，发现N%、hs-CRP于术前术后相比无显著差异(P &gt; 0.05)。见表2。</p><p>将7例患者手术前1天、术后1天、术后7天肝功能指标CA19-9进行非参数检验的Kruskal Wallis检验，发现ALT于术前术后相比有显著差异(P &lt; 0.05)；GGT差异较显著(P &lt; 0.05)。将CEA、AFP进行方差分析，发现CEA、AFP于术前术后相比无显著差异(P &gt; 0.05)。见表3。</p></sec><sec id="s6"><title>4. 讨论</title><sec id="s6_1"><title>4.1. 病因</title><p>CA19-9因由鼠单克隆抗体116NS19-9识别而命名 [<xref ref-type="bibr" rid="hanspub.19483-ref5">5</xref>] 。CA19-9是一种粘蛋白型的糖类蛋白肿瘤标志物，为细胞膜上的糖脂质，分子量大于1000 kD。在血清中它以唾液粘蛋白形式存在，分布于正常胎儿胰腺、胆囊、肝、肠和正常成年人胰腺、胆管上皮等处 [<xref ref-type="bibr" rid="hanspub.19483-ref6">6</xref>] 。</p><p>胆总管结石患者血清CA19-9升高原因可能与以下因素有关：1) 胆总管结石引起胆道内压增高，刺激胆管上皮分泌增多；2) 胆道梗阻引起胆管上皮细胞分泌的CA19-9蓄积于胆管内，通过内皮细胞大量入血；3) 胆管炎症刺激，粘膜充血水肿，粘膜上皮细胞增殖或粘液分泌旺盛，胆汁中含糖量增多，引起糖类抗原分泌增多 [<xref ref-type="bibr" rid="hanspub.19483-ref7">7</xref>] 。</p><p>本研究结果发现胆总管结石患者术后血清结合胆红素、γ-谷氨酰转肽酶、CA19-9均有显著下降，表明胆总管结石造成的胆道梗阻指标血清结合胆红素和γ-谷氨酰转肽酶与CA19-9改变同步，提示胆道梗阻与CA19-9密切相关。</p></sec><sec id="s6_2"><title>4.2. 诊断</title><p>CA19-9在正常人血清中含量甚微，但在许多恶性肿瘤中尤其是在恶性胆道梗阻疾病(主要是胰头癌和胆总管末端肿瘤)中有明显升高，灵敏度与特异性都在75%~90%。因此CA19-9是目前临床上检测胰腺癌和胆总管末端肿瘤的首选标志物 [<xref ref-type="bibr" rid="hanspub.19483-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.19483-ref9">9</xref>] 。近年来先后有报道在其他恶性肿瘤如肝癌、胃癌、胆囊癌、肺癌等多种肿瘤中有不同程度的异常升高 [<xref ref-type="bibr" rid="hanspub.19483-ref10">10</xref>] 。</p><p>然而，越来越多的研究发现，CA19-9作为一个消化道恶性肿瘤标志物，在许多最终被确诊为良性疾病的患者，其CA19-9也经常高于正常 [<xref ref-type="bibr" rid="hanspub.19483-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.19483-ref12">12</xref>] ，如胆管炎、胆管结石、梗阻性黄疸、胰腺炎、肝硬化等疾病，但多数为轻度升高。临床上单纯胆总管结石伴CA19-9显著升高是罕见的，所以CA19-9值必须结合病史、影像学资料、甚至消化内镜检查，以鉴别疾病的良恶性，从而提高疾病诊断的正确率 [<xref ref-type="bibr" rid="hanspub.19483-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.19483-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.19483-ref15">15</xref>] 。</p></sec><sec id="s6_3"><title>4.3. 治疗</title><p>临床上，我们发现胆管结石合并梗阻性黄疸或胆管炎患者中，有一部分出现血清CA19-9明显升高，随着病情好转、炎症控制及胆管梗阻的解除，血清CA19-9逐渐下降至正常。故CA19-9作为一项在良性胆道疾病中监测病情转归的依据具有一定临床实际意义，一旦原发疾病得到了控制，其CA19-9水平显著下降 [<xref ref-type="bibr" rid="hanspub.19483-ref16">16</xref>] 。本例7名患者在原发病得到控制后血清CA19-9快速降低至正常。相关研究表明，即使是良性疾病也是有恶化为恶性肿瘤的趋势的，如果胆囊结石病人CA19-9水平长期在较高水平不降，胆囊结石合并胆囊癌的几率较大，应引起注意，早期预防其恶变危险性。</p></sec></sec><sec id="s7"><title>5. 结论</title><p>血清CA19-9升高多见于各种消化系统恶性肿瘤患者，但其异常升高也可见于胆总管结石患者，动态监测血清CA19-9水平变化有助于胆道良恶性疾病的鉴别诊断，避免胆道良恶性疾病的误诊和误治。</p></sec><sec id="s8"><title>文章引用</title><p>刘立民,张宗明,刘 卓,张 翀,于宏伟,刘子旭,朱明文,宋蒙蒙,赵 月. 血清CA19-9异常增高的胆总管结石7例诊治体会 Experience of Diagnosis and Treatment of 7 Cases of Common Bile Duct Stones with Abnormal Increase of Serum CA19-9[J]. 外科, 2017, 06(01): 8-12. http://dx.doi.org/10.12677/HJS.2017.61002</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.19483-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Tanaka, N., Okada, S., Ueno, H., et al. (2000) The Usefulness of Serial Changes in Serum CA19-9 Levels in the Diagnosis of Pancreatic Cancer. Pancreas, 20, 378-382. https://doi.org/10.1097/00006676-200005000-00007</mixed-citation></ref><ref id="hanspub.19483-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">朱良如, 侯晓华. 消化系统肿瘤标志物的检测及临床应异[J]. 中国实用内科杂志, 2002, 22(9): 574-576.</mixed-citation></ref><ref id="hanspub.19483-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Akimoto, S., Banshodani, M., Nishihara, M., et al. (2016) Acute Cholecystitis with Significantly Elevated Levels of Serum Carbohydrate Antigen 19-9. Case Reports in Gastroenterology, 10, 410-416. https://doi.org/10.1159/000448068</mixed-citation></ref><ref id="hanspub.19483-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Sheen-Chen, S.M., Sun, C.K., Liu, Y.W., et al. (2007) Extremely Elevated CA19-9 in Acute Cholangitis. Digestive Diseases and Sciences, 52, 3140-3142. https://doi.org/10.1007/s10620-006-9164-7</mixed-citation></ref><ref id="hanspub.19483-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Koprowski, H., Stepleweski, Z., Mitchell, K., et al. (1979) Colorectal Carcinoma Antigens Detected by Hybridoma Antibodies. Somatic Cell and Molecular Genetics, 5, 957-972. https://doi.org/10.1007/BF01542654</mixed-citation></ref><ref id="hanspub.19483-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">孔宪涛. 肿瘤特异抗原的研究现状及检测[J]. 中华检验医学杂志, 2000, 23(1): 56-58.</mixed-citation></ref><ref id="hanspub.19483-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">尹大龙, 张树庚, 刘连新, 等. CA19-9在良性胆道疾病中表达的临床意义[J]. 中国普通外科杂志, 2009, 18(8): 864-866.</mixed-citation></ref><ref id="hanspub.19483-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wong, D., Ko, A.H., Hwang, J., et al. (2008) Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients with Metastatic Pancreatic Cancer Receiving Chemotherapy. Pancreas, 37, 269- 274. https://doi.org/10.1097/MPA.0b013e31816d8185</mixed-citation></ref><ref id="hanspub.19483-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">曾立云, 宋逢林, 彭瑛. 胰腺癌血清CA19-9 和CEA的表达及意义[J]. 中国普通外科杂志, 2008, 17(9): 926-928.</mixed-citation></ref><ref id="hanspub.19483-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">王怀志, 赵玉亭, 赵国强, 等. 胃癌患者血清CA19-9, CA242联合检测[J]. 中国普通外科杂志, 2004, 13(9): 711- 712.</mixed-citation></ref><ref id="hanspub.19483-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">王自正, 李少华, 马伦, 等. 现代医学标记免疫学[M]. 北京: 人民军医出版社, 2000: 57.</mixed-citation></ref><ref id="hanspub.19483-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ito, S. and Gejyo, F. (1999) Elevation of Serum CA19-9 Levels in Benign Diseases. Internal Medicine, 38, 840-841. 
https://doi.org/10.2169/internalmedicine.38.840</mixed-citation></ref><ref id="hanspub.19483-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Yu, H., Yu, T.N. and Cai, X.J. (2013) Tumor Biomarkers: Help or Mislead in the Diagnosis of Xanthogranulomatous Cholecystitis?—Analysis of Serum CA19-9, Carcino-Embryonic Antigen, and CA12-5. Chinese Medical Journal (English), 126, 3044-3047.</mixed-citation></ref><ref id="hanspub.19483-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ince, A.T., Yıldiz, K., Baysal, B., et al. (2014) Roles of Serum and Biliary CEA, CA19-9, VEGFR3, and TAC in Differentiating between Malignant and Benign Biliary Obstructions. The Turkish Journal of Gastroenterology, 25, 162- 169. https://doi.org/10.5152/tjg.2014.6056</mixed-citation></ref><ref id="hanspub.19483-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Lourdusamy, V., Tharian, B. and Navaneethan, U. (2015) Biomarkers in Bile-Complementing Advanced Endoscopic Imaging in the Diagnosis of Indeterminate Biliary Strictures. World Journal of Gastrointestinal Endoscopy, 7, 308- 317.</mixed-citation></ref><ref id="hanspub.19483-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Mann, D.V., Edwards, R., Ho, S., et al. (2000) Elevated Tumor Marker CAl9-9: Clinical Interpretation and Influence of Obstructive Jaundice. European Journal of Surgical Oncology, 26, 474-479. https://doi.org/10.1053/ejso.1999.0925</mixed-citation></ref></ref-list></back></article>